Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNASDAQ:HYPRNASDAQ:ICCMNASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.44+0.8%$2.09$0.17▼$1.98$51.01M0.514.29 million shs10,621 shsHYPRHyperfine$0.79+8.8%$0.70$0.53▼$1.90$62.27M1.01900,761 shs408,654 shsICCMIceCure Medical$1.06+4.9%$1.04$0.48▼$1.66$58.55M0.31478,627 shs581,707 shsXAIRBeyond Air$0.18+0.7%$0.19$0.15▼$0.68$15.46M0.221.54 million shs702,165 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell-0.41%-5.06%-24.92%+1,973.07%+40.23%HYPRHyperfine0.00%+6.39%+11.25%+19.53%-23.40%ICCMIceCure Medical0.00%+4.85%+2.82%-7.11%+43.24%XAIRBeyond Air0.00%+11.88%-4.79%-25.91%-69.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AHYPRHyperfine1.9093 of 5 stars3.32.00.00.00.02.50.6ICCMIceCure Medical2.1233 of 5 stars3.84.00.00.00.00.00.6XAIRBeyond Air3.9147 of 5 stars3.73.00.03.51.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AHYPRHyperfine 2.67Moderate Buy$1.0634.35% UpsideICCMIceCure Medical 3.50Strong Buy$2.50136.07% UpsideXAIRBeyond Air 3.33Buy$1.50737.99% UpsideCurrent Analyst Ratings BreakdownLatest XAIR, HYPR, ICCM, and CTCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/29/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.505/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.68(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,553.28N/AN/A$1.07 per share2.28HYPRHyperfine$12.89M4.76N/AN/A$0.67 per share1.18ICCMIceCure Medical$3.29M17.86N/AN/A$0.12 per share8.83XAIRBeyond Air$3.70M4.18N/AN/A$0.17 per share1.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/7/2025 (Estimated)ICCMIceCure Medical-$15.32M-$0.28N/AN/AN/A-467.37%-182.26%-112.65%8/19/2025 (Estimated)XAIRBeyond Air-$46.62M-$0.79N/AN/AN/A-1,258.46%-233.96%-113.92%8/5/2025 (Estimated)Latest XAIR, HYPR, ICCM, and CTCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025XAIRBeyond Air-$0.14-$0.09+$0.05-$0.09$1.39 million$1.15 million5/28/2025Q1 2025ICCMIceCure Medical-$0.08-$0.06+$0.02-$0.06$0.75 million$0.73 million5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29HYPRHyperfineN/A6.075.48ICCMIceCure Medical0.021.891.48XAIRBeyond Air0.643.202.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%HYPRHyperfine15.03%ICCMIceCure Medical0.62%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%HYPRHyperfine30.98%ICCMIceCure Medical2.44%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHYPRHyperfine19077.83 million53.72 millionOptionableICCMIceCure Medical6055.50 million54.15 millionNot OptionableXAIRBeyond Air7086.37 million69.61 millionOptionableXAIR, HYPR, ICCM, and CTCX HeadlinesRecent News About These CompaniesBeyond Air Inc.June 26, 2025 | barrons.comHere's Why Beyond Air (XAIR) Could be Great Choice for a Bottom FisherJune 26, 2025 | zacks.comBeyond Air (XAIR) Q4 2025 Earnings Call TranscriptJune 21, 2025 | msn.comBeyond Air, Inc. (NASDAQ:XAIR) Q4 2025 Earnings Call TranscriptJune 20, 2025 | msn.comBeyond Air posts narrower-than-feared Q4 loss, shares surge 15%June 18, 2025 | investing.comBeyond Air Reports Strong Revenue Growth and Strategic AdvancesJune 17, 2025 | tipranks.comBeyond Air, Inc. (XAIR) Q4 2025 Earnings Call TranscriptJune 17, 2025 | seekingalpha.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | finance.yahoo.comBeyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue EstimatesJune 17, 2025 | zacks.comBeyond Air Stock Dips After Mixed Q4 Results: Here's What To KnowJune 17, 2025 | benzinga.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | globenewswire.comBeyond Air Submits PMA Supplement Application for Next-Generation LungFit PH II Nitric Oxide GeneratorJune 16, 2025 | quiverquant.comQBeyond Air Submits FDA PMA Supplement for Next Generation LungFit® PHJune 16, 2025 | globenewswire.comBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3, 2025 | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comBeyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric OxideApril 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAIR, HYPR, ICCM, and CTCX Company DescriptionsCarmell NASDAQ:CTCX$2.44 +0.02 (+0.83%) As of 07/3/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Hyperfine NASDAQ:HYPR$0.79 +0.06 (+8.81%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$0.78 -0.01 (-0.76%) As of 07/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.IceCure Medical NASDAQ:ICCM$1.06 +0.05 (+4.85%) Closing price 07/3/2025 03:46 PM EasternExtended Trading$1.06 0.00 (-0.38%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Beyond Air NASDAQ:XAIR$0.18 +0.00 (+0.67%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$0.18 0.00 (-0.56%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
